Thursday, July 9, 2026

pharma · Social Anxiety Disorder · Drug Drug Interaction · VTGN

Vistagen Therapeutics

Vistagen Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
7 Employees
Public company Type
VTGN · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Employees
7
Programs
10
Drugs
3
Patents
6
Intelligence · Clinical Programs

Vistagen Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Vistagen Therapeutics.

Vistagen Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Fasedienol Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule active

    1 trial
  2. Fasedienol Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial
  3. PH94B

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    1 trial
  4. PH94B Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

How many clinical projects does Vistagen Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.